|
|
|
|
 |
 |
GlaxoSmithKline Press Releases |
 |
| Company Profile |
| GlaxoSmithKline |
| Sector |
Healthcare |
| Industry |
Drug Manufacturers - Major |
| Employees |
102695 |
|
Contact Info |
Glaxosmithkline plc
980 Great West Road
Brentford,
TW8 9GS
United Kingdom
Phone: 44 20 8047 5000
Fax: 44 20 8047 7807
Web Site: http://www.gsk.com
|
| GlaxoSmithKline Historical Share Price |
|
|
|
| Company Summary |
| GlaxoSmithKline plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical and consumer health-related products. Its Pharmaceuticals segment manufactures prescription drugs and vaccines that are used in various therapeutic areas, including central nervous system, respiratory, anti-viral, anti-bacterial, oncology and emesis, metabolic, cardiovascular, and urogenital. This segment primarily offers Seretide/Advair for asthma and chronic obstructive pulmonary disease; Avandia group of products for diabetes, Lamictal for epilepsy and bipolar disorder; Wellbutrin, an anti-depressant; Zofran to prevent nausea and vomiting associated with chemotherapy and radiotherapy for cancer; Valtrex for herpes; Coreg for heart disease; Imigran/Imitrex for migraine and cluster headache, and Flixotide/Flovent, an inhaled steroid for the treatment of inflammation associated with asthma and COPD, as well as vaccines. The company's Consumer Healthcare segment offers over-the-counter medicines, oral care, and nutritional healthcare products. Its products comprise Lucozade energy and sports drinks; Aquafresh and Sensodyne toothpastes and mouthwashes; Panadol,a paracetamol/ acetaminophen analgesic; and Ribena, a blackcurrant juice-based drink. GlaxoSmithKline operates in the United States, Europe, Japan, Asia Pacific, the Middle East, Latin America, Africa, and Canada. It has strategic alliances with Theravance, Inc.; Targacept, Inc.; Santaris Pharma A/S; and Anacor Pharmaceuticals, Inc. GlaxoSmithKline also has a research and collaboration agreement with EvoGenix Limited, as well as a collaboration agreement with Synta Pharmaceuticals Corp. to jointly develop and commercialize STA-4783, a small-molecule oxidative stress inducer for the treatment of metastatic melanoma. The company was founded in 1935 and is headquartered in Brentford, the United Kingdom. |
|
|
|
|
10th October, 2007
GlaxoSmithKline and Synta Pharmaceuticals announce development and commercialisation collaboration for STA-4783 in oncology
GlaxoSmithKline and Synta Pharmaceuticals announce development and commercialisation collaboration for STA-4783 in oncology
Issued – Wednesday 10 October 2007, London, UK and Lexington, MA
GlaxoSmithKline (GSK) and Synta Pharmaceuticals Corp ...
|
8th October, 2007
GlaxoSmithKline appoints Andrew Witty CEO designate
GlaxoSmithKline appoints Andrew Witty CEO designate
Issued: 8 October 2007, London, 7am
The Board of GlaxoSmithKline plc (“GSK”) (LSE & NYSE: GSK) today announced the appointment of Andrew Witty as CEO Designate, GlaxoSmithKline ...
|
8th October, 2007
GlaxoSmithKline and Anacor Pharmaceuticals form alliance to develop systemic antivirals and antibiotics based on boron chemistry
GlaxoSmithKline and Anacor Pharmaceuticals form alliance to develop systemic antivirals and antibiotics based on boron chemistry
- Innovative approach to developing anti-infective medicines provides hope for combating problems of resistance -
Issued – Monday 8 October 2007, London, UK & Palo Alto, Calif - GlaxoSmithKline and Anacor Pharmaceuticals today announced that they have entered into a worldwide strategic alliance for the discovery, development and commercialisation of novel medicines for viral and bacterial diseases ...
|
4th October, 2007
GSK seeks prequalification for Cervarix™ from the World Health Organization after obtaining marketing approval in Europe
GSK seeks prequalification for Cervarix™ from the World Health Organization after obtaining marketing approval in Europe
For business and financial press only
Issued — Thursday 4 October 2007, London, UK & Rixensart, Belgium
Goal is to speed availability in the developing world
GlaxoSmithKline (GSK) announced today that it has submitted a file on its cervical cancer vaccine, Cervarix™, to the World Health Organization (WHO) for pre-qualification, following the granting of a marketing authorisation approval by regulatory authorities in Europe on 20 September ...
|
2nd October, 2007
GSK applies for licence to market OTC weight loss product In Europe
GSK applies for licence to market OTC weight loss product In Europe
For business and financial media
Issued – Tuesday 2 October 2007, London, UK - GlaxoSmithKline (GSK) today announced its marketing application for non-prescription orlistat 60mg for weight loss has been accepted for review by the European Agency for the Evaluation of Medicinal Products (EMEA) ...
|
28th September, 2007
GSK submits Cervarix™ licence application to Japan’s health authorities
GSK submits Cervarix™ licence application to Japan’s health authorities
For UK business and financial media (not for distribution to US media)
Issued – 28 September 2007, London (UK) and Rixensart (Belgium) - GlaxoSmithKline (GSK) today announced that it has submitted a licence application for its cervical cancer candidate vaccine Cervarix™ to the Japanese Ministry of Health, Labor and Welfare (MHLW) ...
|
28th September, 2007
GlaxoSmithKline PLC announces change to the Board of Directors
GlaxoSmithKline PLC announces change to the Board of Directors
Issued – 28 September 2007, London
GlaxoSmithKline plc (GSK) announces that Professor Sir Roy Anderson has been appointed a Non-Executive Director and will join the Board of the Company with effect from 1 October 2007 ...
|
27th September, 2007
GlaxoSmithKline helps form the Serious Adverse Events Consortium
GlaxoSmithKline helps form the Serious Adverse Events Consortium
PHILADELPHIA, PA – September 27, 2007 - GlaxoSmithKline (NYSE: GSK)announced today that it will join with other pharmaceutical companies, academic institutions and the U.S ...
|
25th September, 2007
GlaxoSmithKline named to Working Mother "100 Best Companies" list
GlaxoSmithKline named to Working Mother "100 Best Companies" list
For the 16th year, GSK is recognized for encouraging and facilitating mothers’ return to the workforce
US Media inquiries:
Michael McTigue
(215)751 7709
PHILADELPHIA, PA– SEPTEMBER 25, 2007– For the sixteenth consecutive year, GlaxoSmithKline (NYSE: GSK) has been named one of the “100 Best Companies” by Working Mother magazine, the company announced today ...
|
24th September, 2007
Cervarix, GSK's cervical cancer vaccine, approved In Europe
Cervarix, GSK's cervical cancer vaccine, approved In Europe
GlaxoSmithKline (GSK) today announced that the European Commission has granted a marketing authorisation for its cervical cancer vaccine, CervarixTM for all 27 European member states* ...
|
|
|
|
Next 10 » |
|
|
|
|
